Affigen Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Liquidation

Affigen General Information


Developer of tumor-identifying therapies designed to treat cancer. The company's therapeutic technology targets cell lineage-specific tumor proteins that maximize both anti-tumor activity and safety in patients with critically unmet medical needs, enabling the patients to combat against cancer with extreme sensitivity and precision.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 3 Greenway Plaza
  • Suite 1000
  • Houston, TX 77046
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Affigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation 01-Jan-2019 0000 Completed Bankruptcy: Liquidation
2. Early Stage VC (Series A) 21-Feb-2017 0000 0000 Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2016 Completed Startup
To view Affigen’s complete valuation and funding history, request access »